Journal of Medicinal Chemistry · 1990 · 22 citations · 0 references
PharmacyPharmacokineticsPharmacologyBioavailabilityClinical PharmacologyDrug DiscoveryDrug SolubilityGastrointestinal PharmacologyOral BioavailabilityRenal PharmacologySolubility EnhancementSolubility OptimizationBlood PressureLow SolubilityRenin-angiotensin System InhibitorsRenin-angiotensin-aldosterone System InhibitionRenin-angiotensin-aldosterone System InhibitorsSolubilitySolubility DeterminationSolubility-limited Bioavailability
Incorporation of nonreactive polar functionalities at the C- and N-termini of renin inhibitors led to the development of a subnanomolar compound (21) with millimolar solubility. This inhibitor demonstrated excellent efficacy and a long duration of action upon intravenous administration to monkeys. While activity was also observed intraduodenally, a comparison of the blood pressure responses indicated low bioavailability. Subsequent experiments in rats showed that, although the compound was absorbed from the gastrointestinal tract, extensive liver extraction severely limited bioavailability.